Medicare Expands Access to Wegovy for Obesity Management Starting July 2026
The Centers for Medicare & Medicaid Services (CMS) announced that starting July 1, 2026, Medicare beneficiaries living with obesity will have access to Wegovy® (semaglutide) for a $50 monthly copay. This initiative, known as the Medicare GLP-1 Bridge, aims to provide eligible patients with access to both the injection and tablet forms of Wegovy®, which is FDA-approved for weight management and reducing cardiovascular risks in patients with heart disease. Novo Nordisk, the manufacturer of Wegovy®, is collaborating with CMS to ensure the program's implementation and to raise awareness among eligible seniors. The program will run through the end of 2027 and is part of a broader effort to make FDA-approved treatments more accessible to Medicare patients. 
